Daubert G P
Department of Emergency Medicine & Pediatrics, Children's Hospital of Michigan Regional Poison Control Center, Wayne State University School of Medicine, Detroit, MI, USA.
J Clin Pharm Ther. 2006 Jun;31(3):289-92. doi: 10.1111/j.1365-2710.2006.00734.x.
Brimonidine is a topical alpha-2 agonist commonly used in the treatment of glaucoma. Brimonidine toxicity resembles that of clonidine overdose and is probably due to both imidazoline and alpha-2 adrenergic receptor effects. We report a case of a 6-week-old infant with congenital glaucoma who developed bradycardia and hypotension following the administration of brimonidine 0.15% ophthalmic solution. There are occasional reports of brimonidine toxicity in the paediatric population but its overall safety profile in children<2 years of age remains uncertain. Brimonidine is not dosed by weight and therefore paediatric patients may be at increased risk for systemic toxicity. It is recommended that the use of this medication be carefully considered in children<2 years of age. Physicians should be aware of its side effect profile because of its general use in the paediatric population.
溴莫尼定是一种常用于治疗青光眼的局部用α-2激动剂。溴莫尼定毒性与可乐定过量中毒相似，可能是由于咪唑啉和α-2肾上腺素能受体效应共同所致。我们报告一例6周大的先天性青光眼婴儿，在使用0.15%溴莫尼定滴眼液后出现心动过缓和低血压。儿科人群中偶尔有溴莫尼定毒性的报告，但2岁以下儿童使用该药的总体安全性仍不确定。溴莫尼定不是按体重给药，因此儿科患者发生全身毒性的风险可能增加。建议在2岁以下儿童中谨慎考虑使用这种药物。由于该药在儿科人群中的广泛使用，医生应了解其副作用情况。
